Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(02): 99-104
DOI: 10.4103/0971-5851.158838
ORIGINAL ARTICLE

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors

Supriya Mallick
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Ajeet Kumar Gandhi
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Nikhil P. Joshi
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Anupam Kumar
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Tarun Puri
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Daya Nand Sharma
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Kunhi Parambath Haresh
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Subhash Gupta
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Pramod Kumar Julka
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Goura Kisor Rath
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Chitra Sarkar
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Pediatric glioblastoma (pGBM) patients are underrepresented in major trials for this disease. We aimed to explore the outcome of pGBM patients treated with concurrent and adjuvant temozolomide (TMZ). Materials and Methods: 23 patients of pGBM treated from 2004 to 2010 were included in this retrospective analysis. Adjuvant therapy included conformal radiation 60 gray at 2 gray/fraction daily over 6 weeks with concurrent TMZ 75 mg/m 2 followed by six cycles of adjuvant TMZ 150-200 mg/m 2 (day 1-5) every 4 weeks. Kaplan-Meier estimates of overall survival (OS) were determined. Univariate analysis with log-rank test was used to determine the impact of prognostic variables on survival. Results: Median age at presentation was 11.5 years (range: 7-19 years) and M:F ratio was 15:8. All patients underwent maximal safe surgical resection; 13 gross total resection and 10 sub-total resection. At a median follow-up of 18 months (range: 2.1-126 months), the estimated median OS was 41.9 months. The estimated median OS for patients receiving only concurrent TMZ was 8 months while that for patients receiving concurrent and adjuvant TMZ was 41.9 months (P = 0.081). Estimated median OS for patients who did not complete six cycles of adjuvant TMZ was 9.5 months versus not reached for those who completed at least six cycles (P = 0.0005). Other prognostic factors did not correlate with survival. Conclusions: Our study shows the benefit of TMZ for pGBM patients. Both concurrent and adjuvant TMZ seem to be important for superior OS in this group of patients.

Keywords

Pediatric glioblastoma - radiotherapy - temozolomide


Publication History

Article published online:
12 July 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kun LE. Supratentorial brain tumors except ependymomas; brain tumors in babies and very young children. In: Halperin EC, editors. Pediatric Radiation Oncology. 4 th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 41.
  • 2 Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006;2:494-503.
  • 3 Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
  • 4 Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007;48:403-7.
  • 5 Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol 2006;24:3431-7.
  • 6 Srivastava A, Jain A, Jha P, Suri V, Sharma MC, Mallick S, et al. MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst 2010;26:1613-8.
  • 7 Ansari M, Nasrolahi H, Kani AA, Mohammadianpanah M, Ahmadloo N, Omidvari S, et al. Pediatric glioblastoma multiforme: A single-institution experience. Indian J Med Paediatr Oncol 2012;33:155-60.
  • 8 Perkins SM, Rubin JB, Leonard JR, Smyth MD, El Naqa I, Michalski JM, et al. Glioblastoma in children: A single-institution experience. Int J Radiat Oncol Biol Phys 2011;80:1117-21.
  • 9 Sánchez-Herrera F, Castro-Sierra E, Gordillo-Domínguez LF, Vaca-Ruiz MA, Santana-Montero B, Perezpeña-Diazconti M, et al. Glioblastoma multiforme in children: Experience at Hospital Infantil de Mexico Federico Gomez. Childs Nerv Syst 2009;25:551-7.
  • 10 Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, et al. Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 2010;6:145-9.
  • 11 Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
  • 12 Pollack IF, Boyett JM, Yates AJ, Burger PC, Gilles FH, Davis RL, et al. The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience. Neuro Oncol 2003;5:197-207.
  • 13 Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-9.
  • 14 Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80.
  • 15 Dohrmann GJ, Farwell JR, Flannery JT. Glioblastoma multiforme in children. J Neurosurg 1976;44:442-8.
  • 16 Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, et al. Supratentorial malignant gliomas in childhood: A single institution perspective. Cancer 1997;80:497-504.
  • 17 Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011; 18:66-70.
  • 18 Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children′s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684-91.
  • 19 Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G. Temozolomide in paediatric high-grade glioma: A key for combination therapy? Br J Cancer 2004;91:425-9.
  • 20 Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. Temozolomide in the treatment of high-grade gliomas in children: A report from the Children′s Oncology Group. Neuro Oncol 2011;13:317-23.